Lexaria Bioscience Corp (CSE:LXX) (OTC:LXRP) has won approval from the ethics board of a European university research hospital to conduct an exploratory clinical study of CBD formulated with its DehydraTECH drug delivery technology as a treatment for hypertension patients.
The study will evaluate blood pressure reduction in 24 pre- or mild hypertension patients, who will receive a 300 milligram dose of CBD with or without DehydraTECH. The primary endpoints are blood pressure and heart rate.
The company expects to have the results of the study by November.
READ: Lexaria Bioscience files application with senior US stock exchange to request an uplisting of its common stock
"Lexaria believes that this study, if positive, will strengthen its value proposition pursuant to its intention to seek out pharmaceutical industry partnering opportunities with its DehydraTECH platform technology," CEO Chris Bunka said in a statement. "Positive results in this study are expected to be of particular interest to the antihypertensive products sector that is valued at over $22 billion."
Hypertension affects more than 1 billion people globally, the company said, but only 13% of those affected have the condition under control, according to the Centers for Disease Control and Prevention.
DehydraTECH works by improving the delivery of substances such as CBD, which is fat-soluble and thus poorly absorbed by the body when taken orally.
The study is meant to compliment a 2018 study, which showed a 90mg dose of Lexaria's TurboCBD oral capsule formulation provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream and larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD, the company said.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel